[go: up one dir, main page]

PT109645A - A DEFLAMINE POLYPEPTIDES COMPOSITION, THEIR USE IN A METHOD OF TREATMENT AND THEIR PREPARATION, VECTORS OF NUCLEIC ACID EXPRESSING AND ANTIBODY FOR THOSE POLYPEPTIDES - Google Patents

A DEFLAMINE POLYPEPTIDES COMPOSITION, THEIR USE IN A METHOD OF TREATMENT AND THEIR PREPARATION, VECTORS OF NUCLEIC ACID EXPRESSING AND ANTIBODY FOR THOSE POLYPEPTIDES

Info

Publication number
PT109645A
PT109645A PT109645A PT10964516A PT109645A PT 109645 A PT109645 A PT 109645A PT 109645 A PT109645 A PT 109645A PT 10964516 A PT10964516 A PT 10964516A PT 109645 A PT109645 A PT 109645A
Authority
PT
Portugal
Prior art keywords
polypeptides
composition
deflamine
vectors
antibody
Prior art date
Application number
PT109645A
Other languages
Portuguese (pt)
Inventor
Manuel De Seixas Boavida Ferreira Ricardo
Isabel Gusmão Lima Ana
Carapinha Caldeira Batista Saúde Filipe
Patrícia Mota Guerreiro Joana
Original Assignee
Inst Superior Agronomia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Superior Agronomia filed Critical Inst Superior Agronomia
Priority to PT109645A priority Critical patent/PT109645A/en
Priority to EP17809192.2A priority patent/EP3518957B1/en
Priority to MX2019003751A priority patent/MX2019003751A/en
Priority to KR1020197010566A priority patent/KR20190061015A/en
Priority to CN201780072761.XA priority patent/CN110214017B/en
Priority to JP2019538725A priority patent/JP7510255B2/en
Priority to PCT/EP2017/075020 priority patent/WO2018060528A2/en
Priority to US16/338,485 priority patent/US20200113969A1/en
Priority to CA3037800A priority patent/CA3037800A1/en
Priority to BR112019006174A priority patent/BR112019006174A2/en
Priority to AU2017334047A priority patent/AU2017334047B2/en
Publication of PT109645A publication Critical patent/PT109645A/en
Priority to IL265708A priority patent/IL265708A/en
Priority to CL2019000846A priority patent/CL2019000846A1/en
Priority to CONC2019/0003865A priority patent/CO2019003865A2/en
Priority to ZA201902689A priority patent/ZA201902689B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UMA COMPOSIÇÃO DE POLIPÉPTIDOS PARA UTILIZAÇÃO NUM MÉTODO DE TRATAMENTO DO CORPO HUMANO OU DE UM ANIMAL POR TERAPIA, EM QUE A REFERIDA TERAPIA É, PREFERENCIALMENTE, PREVENIR OU TRATAR INFLAMAÇÃO OU CANCRO, OU PROPORCIONAR UM NUTRACÊUTICO. A REFERIDA COMPOSIÇÃO COMPREENDE 1 A 100 POLIPÉPTIDOS DIFERENTES QUE COMPREENDEM, CADA UM, UMA SEQUÊNCIA QUE É A MESMA QUE QUALQUER UMA DAS SEQ. ID N.º 8 A 190 OU É UMA PORÇÃO DE QUALQUER SEQ. ID N.º 8 A 190 QUE TEM PELO MENOS 5, 10, 20 OU 50 RESÍDUOS DE AMINOÁCIDOS DE COMPRIMENTO E/OU UM HOMÓLOGO DA SEQUÊNCIA DEFINIDA EM (A), QUE DE PREFERÊNCIA TEM PELO MENOS 70% DE IDENTIDADE PARA (A), EM QUE A REFERIDA COMPOSIÇÃO NÃO COMPREENDE, OPCIONALMENTE, QUALQUER OUTRO POLIPÉPTIDO.A COMPOSITION OF POLYPEPTIDES FOR USE IN A METHOD FOR TREATING THE HUMAN BODY OR AN ANIMAL THERAPY, wherein said therapy is preferably preventing or treating inflammation or cancer, or providing a nutrient. The foregoing composition comprises 1 to 100 different polypeptides which comprise, each, a sequence which is the same as any one of the seq. ID NO. 8 TO 190 OR IS A PORTION OF ANY SEQ. ID NO. 8 TO 190 HAVING AT LEAST 5, 10, 20 OR 50 AMINO ACID WASTES OF LENGTH AND / OR A HOMOLOGUE OF THE SEQUENCE DEFINED IN (A), WHICH OF PREFERENCE HAS AT LEAST 70% OF IDENTITY FOR (A) , Wherein the said composition does not, optionally, comprise any other polypeptide.

PT109645A 2016-09-30 2016-09-30 A DEFLAMINE POLYPEPTIDES COMPOSITION, THEIR USE IN A METHOD OF TREATMENT AND THEIR PREPARATION, VECTORS OF NUCLEIC ACID EXPRESSING AND ANTIBODY FOR THOSE POLYPEPTIDES PT109645A (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
PT109645A PT109645A (en) 2016-09-30 2016-09-30 A DEFLAMINE POLYPEPTIDES COMPOSITION, THEIR USE IN A METHOD OF TREATMENT AND THEIR PREPARATION, VECTORS OF NUCLEIC ACID EXPRESSING AND ANTIBODY FOR THOSE POLYPEPTIDES
US16/338,485 US20200113969A1 (en) 2016-09-30 2017-10-02 Therapeutic protein
CA3037800A CA3037800A1 (en) 2016-09-30 2017-10-02 Therapeutic protein
KR1020197010566A KR20190061015A (en) 2016-09-30 2017-10-02 Therapeutic protein
CN201780072761.XA CN110214017B (en) 2016-09-30 2017-10-02 Therapeutic proteins
JP2019538725A JP7510255B2 (en) 2016-09-30 2017-10-02 Therapeutic Proteins
PCT/EP2017/075020 WO2018060528A2 (en) 2016-09-30 2017-10-02 Therapeutic protein
EP17809192.2A EP3518957B1 (en) 2016-09-30 2017-10-02 Therapeutic protein
MX2019003751A MX2019003751A (en) 2016-09-30 2017-10-02 Therapeutic protein.
BR112019006174A BR112019006174A2 (en) 2016-09-30 2017-10-02 therapeutic protein
AU2017334047A AU2017334047B2 (en) 2016-09-30 2017-10-02 Therapeutic protein
IL265708A IL265708A (en) 2016-09-30 2019-03-28 Therapeutic protein
CL2019000846A CL2019000846A1 (en) 2016-09-30 2019-03-29 Therapeutic protein.
CONC2019/0003865A CO2019003865A2 (en) 2016-09-30 2019-04-16 Therapeutic protein
ZA201902689A ZA201902689B (en) 2016-09-30 2019-04-29 Therapeutic protein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PT109645A PT109645A (en) 2016-09-30 2016-09-30 A DEFLAMINE POLYPEPTIDES COMPOSITION, THEIR USE IN A METHOD OF TREATMENT AND THEIR PREPARATION, VECTORS OF NUCLEIC ACID EXPRESSING AND ANTIBODY FOR THOSE POLYPEPTIDES

Publications (1)

Publication Number Publication Date
PT109645A true PT109645A (en) 2018-04-02

Family

ID=62107537

Family Applications (1)

Application Number Title Priority Date Filing Date
PT109645A PT109645A (en) 2016-09-30 2016-09-30 A DEFLAMINE POLYPEPTIDES COMPOSITION, THEIR USE IN A METHOD OF TREATMENT AND THEIR PREPARATION, VECTORS OF NUCLEIC ACID EXPRESSING AND ANTIBODY FOR THOSE POLYPEPTIDES

Country Status (1)

Country Link
PT (1) PT109645A (en)

Similar Documents

Publication Publication Date Title
BR112019011277A2 (en) polynucleotide, recombinant expression system, vector, polypeptide, recombinant cell, isolated synthetic immune receptor polypeptide or polypeptide heterodimer, immune effector cell or stem cell, immune or effector cell population, methods of manufacturing an immune effector cell that expresses sir, generating an RNA-modified cell population, providing anti-disease immunity and treating or preventing a disease, composition, use or method, kit, and amino acid sequence.
BR112019018307A2 (en) PLATFORM FOR IDENTIFICATION OF IMMUNOGENIC PEPTIDES BASED ON POPULATION
BR112018068906A2 (en) composition, method, risk reduction method, prevention or treatment of an individual having an autoimmune disease or disorder, method of inducing degradation of a target protein in a cell, method for reducing risk, preventing or treating a disease state or disorder in a patient wherein the unregulated protein activity is responsible for said disease or condition, method for reducing the risk, preventing or treating cancer in an individual, and method of treating a genetic disease or disorder in an individual
BR112017016336A2 (en) single agonist binding proteins?
IL272593A (en) Methods for treating degenerative joint disease with cannabidiol gel through the skin
MX378579B (en) USE OF PRIDOPIDINE TO IMPROVE COGNITIVE FUNCTION AND FOR THE TREATMENT OF ALZHEIMER'S DISEASE.
BR112021015751A2 (en) Gene therapy vectors for the treatment of danon's disease
CY1123501T1 (en) USE OF RESLIZUMAB IN THE TREATMENT OF MODERATE TO SEVERE EOSINOPHILIC ASTHMA
BR112015026247A2 (en) methods for cancer treatment using tor kinase inhibitor combination therapy
MX2017014730A (en) Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3).
MX2024005705A (en) COMPOSITIONS OF IONIC LIQUIDS.
BR112017019343A2 (en) use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer therewith
MX2022002056A (en) COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE.
BR112018069930A2 (en) powder agonists, compounds, pharmaceutical compositions, and methods of using them
BR112021020777A2 (en) csfv subunit vaccine
MX2020009532A (en) MODIFIED OLIGONUCLOTIDES FOR USE IN THE TREATMENT OF TAUOPATHIES.
EA201991015A1 (en) MODIFIED PEPTIDES
CL2023003260A1 (en) Compositions and methods for the treatment of sensorineural hearing loss using dual stereocilin vector systems.
BR112017022205A2 (en) human anti-vegfr2 antibody for antiangiogenic and targeted cancer therapy
BR112019020386A2 (en) human pd-1 peptide vaccines and their uses
CL2019000846A1 (en) Therapeutic protein.
BR112018015826A2 (en) egfl6 specific monoclonal antibodies and methods of use
BR112016014601A2 (en) DERMATOLOGICAL COMPOSITION, APPLICATOR DEVICE AND METHOD FOR PREPARING A DERMATOLOGICAL COMPOSITION
PT109645A (en) A DEFLAMINE POLYPEPTIDES COMPOSITION, THEIR USE IN A METHOD OF TREATMENT AND THEIR PREPARATION, VECTORS OF NUCLEIC ACID EXPRESSING AND ANTIBODY FOR THOSE POLYPEPTIDES
BR112019007028A2 (en) Pharmaceutical Methods and Compositions for the Treatment of Kidney Cancer

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 20180131